Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4166441 | 0.88 | KDM4E (0.32) | KDM4EGAALMNATP53MAPT | |
| SCHEMBL3255223 | 0.87 | KDM4E (0.37) | KDM4EESR2ESR1GAAMEN1 | |
| Hydrochloric Acid SCHEMBL4155353 | 0.85 | KDM4E (0.34) | KDM4EESR2ESR1GAALMNA | |
| SCHEMBL4153570 | 0.84 | SCN9A (0.32) | KDM4ELMNATP53MAPT | |
| Butyric Acid SCHEMBL4159977 | 0.83 | KDM4E (0.35) | KDM4EESR2ESR1MEN1ADRB2 | |
| SCHEMBL4166910 | 0.83 | KDM4E (0.39) | KDM4EGAAMEN1ADRB2RECQL | |
| SCHEMBL4155240 | 0.82 | KDM4E (0.35) | KDM4EGAALMNATP53MAPT | |
| SCHEMBL4163711 | 0.82 | PARP1 (0.33) | — | |
| SCHEMBL4165089 | 0.82 | GAA (0.40) | KDM4EGAAMEN1ADRB2RECQL | |
| SCHEMBL4154816 | 0.81 | KDM4E (0.44) | KDM4EGAAMEN1ADRB2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | KDM4E 1970/4885ESR2 1588/4885ESR1 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.